ALLMEDTECH.COM
ALLMEDTECH.COM
MEDICAL, SURGICAL, DENTAL,
PHARMACEUTICALS , OBGYN,
VETERINARY & PET SUPPLIES,
DIAGNOSTIC LAB, COSMETICS,
VACCINES , INJECTABLES , IV ,
GENERIC & OTC MEDICATIONS ,
PHARMACY'S AND MED-SPORT
SUPPLIES & EQUIPMENTS
TOLL FREE: 1-800-939-6944
Settle Injectable
1.5 ml Vial
NOVAVIVE 5555
1.5 ml Vial
NOVAVIVE 5555
Product Description
Settle Injectable
1.5 ml Vial
NOVAVIVE 5555
Specifications Active Ingredient: Emulsion of purified mycobacterium cell walls Volume: 1.5 ml Package Quantity: 1/Pkg Presentation: Liquid Container Type: Vial Delivery Type: Injection Product Details SETTLE® is immunotherapeutic licensed to treat equine endometritis - one of the root causes of poor conception rates. Supportive research has demonstrated positive results not only for rapidly resolving uterine infection, but also improving overall uterine health. A new technological approach for a costly, industry-wide reproduction problem Normalizes sub-optimal responses to infection and endometritis in problem mares Proven both safe and effective in U.S. mares over past two breeding seasons Works as a stand alone treatment or hand-in-hand with other therapies to synergistically improve treatment outcomes USDA-licensed to treat equine endometritis caused by Streptococcus zooepidemicus Stimulates the mare’s own immune system, helping it to recognize, respond and begin repair of damaged tissue and infection Addresses broad range of endometritis issue: infection, inflammation and healing Permits earliest return of the equine uterus to a “breeding-ready status” Intravenous or intr-uterine administration routes provide similar therapeutic results
1.5 ml Vial
NOVAVIVE 5555
Specifications Active Ingredient: Emulsion of purified mycobacterium cell walls Volume: 1.5 ml Package Quantity: 1/Pkg Presentation: Liquid Container Type: Vial Delivery Type: Injection Product Details SETTLE® is immunotherapeutic licensed to treat equine endometritis - one of the root causes of poor conception rates. Supportive research has demonstrated positive results not only for rapidly resolving uterine infection, but also improving overall uterine health. A new technological approach for a costly, industry-wide reproduction problem Normalizes sub-optimal responses to infection and endometritis in problem mares Proven both safe and effective in U.S. mares over past two breeding seasons Works as a stand alone treatment or hand-in-hand with other therapies to synergistically improve treatment outcomes USDA-licensed to treat equine endometritis caused by Streptococcus zooepidemicus Stimulates the mare’s own immune system, helping it to recognize, respond and begin repair of damaged tissue and infection Addresses broad range of endometritis issue: infection, inflammation and healing Permits earliest return of the equine uterus to a “breeding-ready status” Intravenous or intr-uterine administration routes provide similar therapeutic results